Syngen Biotech Co Ltd (8279)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Syngen Biotech Co Ltd (8279) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013348
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:15
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Syngen Biotech Co Ltd (Syngen), a part of Standard Chem& Pharm Co Ltd, is a biotechnology company that specializes in strain identification, micro-organism fermentation, recovery, and purification. The company research, develops, manufactures and distributes active pharmaceutical ingredients (APIs), biology fermentation products, nutritional ingredients, biology agriculture and aquaculture products, and sale of preventive medicine. Its APIs include Mupirocin, an antibiotic against gram-positive and gram-negative bacteria used for the treatment of superficial infections such as impetigo; infections due to staphylococci and streptococci; and also used to control infected eczema, wounds and burns. The company’s nutritional ingredients include probiotics, medicinal fungi, and entomogenous fungi. Syngen Biotech is headquartered in Tainan, Taiwan.

Syngen Biotech Co Ltd (8279) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deal Details 9
Equity Offering 9
Syngen Biotech Raises USD5.5 Million in Public Offering of Shares 9
Syngen Biotech Raises USD5 million in Public Offering of Shares 10
Syngen Biotech Raises USD1.5 Million in Public Offering of Shares 11
Syngen Biotech Co Ltd – Key Competitors 12
Syngen Biotech Co Ltd – Key Employees 13
Syngen Biotech Co Ltd – Locations And Subsidiaries 14
Head Office 14
Appendix 15
Methodology 15
About GlobalData 15
Contact Us 15
Disclaimer 15

List of Tables
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
Syngen Biotech Raises USD5.5 Million in Public Offering of Shares 9
Syngen Biotech Raises USD5 million in Public Offering of Shares 10
Syngen Biotech Raises USD1.5 Million in Public Offering of Shares 11
Syngen Biotech Co Ltd, Key Competitors 12
Syngen Biotech Co Ltd, Key Employees 13

★海外企業調査レポート[Syngen Biotech Co Ltd (8279)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Pathogenica Inc-医療機器分野:企業M&A・提携分析
    Summary Pathogenica Inc (Pathogenica) is a medical device company that offers multiplex bacterial detection and genotyping kit. The company provides medical diagnostic sequencing products and services for research and clinical use. Its scientific consulting services offers experimental design, DxSeq …
  • KeyCorp (KEY):企業の財務・戦略的SWOT分析
    KeyCorp (KEY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • VPK Packaging Group NV:企業の戦略・SWOT・財務情報
    VPK Packaging Group NV - Strategy, SWOT and Corporate Finance Report Summary VPK Packaging Group NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Eni SpA Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    Eni SpA Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary Eni SpA (Eni) is an integrated oil and gas company. The company carries out oil and natural gas exploration, field development and production activities. It also involved in supply, trading and shipping of n …
  • Centene Corp (CNC):製薬・医療:M&Aディール及び事業提携情報
    Summary Centene Corp (Centene) is a healthcare service provider that offers services to government sponsored healthcare programs with focus on under-insured and uninsured individuals. It provides health plans through Medicaid, Medicare and Health Insurance Marketplace contracts; and other health sol …
  • Prudential Plc:企業のM&A・事業提携・投資動向
    Prudential Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Prudential Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Volkswagen AG:企業の戦略・SWOT・財務情報
    Volkswagen AG - Strategy, SWOT and Corporate Finance Report Summary Volkswagen AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Central Glass Co Ltd (4044):企業の財務・戦略的SWOT分析
    Central Glass Co Ltd (4044) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • NOF Corp (4403):企業の財務・戦略的SWOT分析
    NOF Corp (4403) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Pioneer Natural Resources Co (PXD)-石油・ガス分野:企業M&A・提携分析
    Summary Pioneer Natural Resources Company (Pioneer) is an independent oil and natural gas exploration and production company. Its principally operates in Eagle Ford Shale, Permian Basin, Raton Basin, and West Panhandle. In Permian Basin, the company carries out its exploration and production activit …
  • Hankook Tire & Technology Co Ltd (161390):企業の財務・戦略的SWOT分析
    Hankook Tire & Technology Co Ltd (161390) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Lonza Group Ltd (LONN)-製薬・医療分野:企業M&A・提携分析
    Summary Lonza Group Ltd (Lonza) is a biopharmaceutical company that manufactures and develops chemical and biological active pharmaceutical ingredients, and other products and services. The company offers active pharmaceutical ingredients, stem cell therapies, drinking water sanitizers, vitamin B co …
  • Enel Americas SA:企業の戦略・SWOT・財務情報
    Enel Americas SA - Strategy, SWOT and Corporate Finance Report Summary Enel Americas SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Dr. Reddy’s Research and Development BV-医療機器分野:企業M&A・提携分析
    Summary Dr. Reddy’s Research and Development BV (Dr. Reddy’s Research and Development), a subsidiary of Dr. Reddy's Laboratories Ltd is a drug formulation and manufacturing service provider that develops and manufactures improved injectable pharmaceuticals. The company offers services such as formul …
  • Sequa Petroleum NV (MLSEQ):企業の財務・戦略的SWOT分析
    Summary Sequa Petroleum NV (Sequa Petroleum) is an oil and gas company. It develops, acquires, monetises, produces and finances oil and natural gas assets. The company holds assets in Europe, Central and West Africa and the Middle East. Sequa Petroleum has a large development and producing area in N …
  • Magellan Midstream Partners LP (MMP):企業の財務・戦略的SWOT分析
    Magellan Midstream Partners LP (MMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Keio Corporation:企業の戦略・SWOT・財務分析
    Keio Corporation - Strategy, SWOT and Corporate Finance Report Summary Keio Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Cellectricon AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Cellectricon AB (Cellectricon) is an advanced cell-based discovery service provider. The company offers automated cell-based screening technologies for drug discovery and basic research. It provides Cellaxess, a platform that allows the researchers to address critical bottlenecks in the drug …
  • Sareum Holdings Plc (SAR)-製薬・医療分野:企業M&A・提携分析
    Summary Sareum Holdings Plc (Sareum) is a drug discovery and development company that produces targeted small molecule therapeutics for treating cancer and autoimmune diseases. The drug research programs of the company are based on its proprietary drug discovery technology, SKIL (Sareum Kinase Inhib …
  • Sun BioPharma Inc (SNBP):企業の財務・戦略的SWOT分析
    Summary Sun BioPharma Inc (Sun BioPharma), formerly Cimarron Medical Inc is a biopharmaceutical company that develops disruptive therapeutics for treatment of pancreatic cancer and pancreatitis. The company’s pipeline products include SBP-101, SBP-102 and SBP-103. Its SBP-101 produces superior anti- …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆